TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects between 18-75 years of age~2. Subject able and willing to comply with study protocol requirements and able to understand the informed consent~3. Non-pregnant female willing to take urine pregnancy test~4. Chronic venous ulceration of the lower extremity~   * Defined: wound of greater than 1 month in duration~  * Diagnosis based on clinical assessment and/or venous studies~  * \<100 cm2 area and \<10cm at the widest diameter~Exclusion Criteria:~1. Active infection (redness, swelling, pain, purulence)~2. Untreated osteomyelitis or current osteomyelitis~3. Allergy or sensitivity to wound study products~4. Malignancy~5. Plantar surface wounds~6. BMI (Body Mass Index) ≥50~7. Uncontrolled diabetes (HbA1c\>12%) at the time of study screening~8. End stage renal disease~9. Undergoing chemotherapy/radiation therapy~10. Non-dopplerable pedal pulses or otherwise diagnosed with peripheral arterial disease or any contraindication to compression therapy~11. Any previous wound care therapy including negative pressure therapy, ultrasound therapy, BAT, or STSG within the previous 30 days of enrollment; this excludes compression therapy~12. Greater than 35% wound surface area reduction in size at 2 weeks after initial screening visit~13. Pregnancy~14. Subject has any condition that, in the opinion of the investigator, makes the subject inappropriate to take part in this study~15. Subject unwilling or unable to comply with protocol requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ActiVAC System+ Compression therapy (Type: ACTIVE_COMPARATOR): ActiVAC System + Compression therapy group consisting of the application of this device along with compression therapy.
- Compression therapy only (Type: OTHER): Standard of Care compression therapy only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stone Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged ≥ 18 years to ≤ 75 years.~* One urinary stone-apparent on a computed tomography (CT) scan within 14 days prior to study enrollment~* Stone size, as estimated by pre-procedure CT, with all dimensions 15 mm or less.~* Provides written informed consent~* Understands and accepts the study requirements~Exclusion Criteria:~* Age less than 18 years of age or over 75 years of age~* Diagnosis of radiolucent stones~* Diagnosis of stones in the lower pole of kidney~* History of cystinuria~* Urine pH below 5.5~* Current untreated urinary tract infection~* Pregnancy~* Coagulation abnormality or taking prescription anticoagulants. Aspirin usage will be discontinued at least 7 days prior to enrollment at the discretion of the attending physician.~* Mobility issues - unable to comfortably lie still for up to 30 minutes or unable to roll from back to side~* Known hypersensitivity to conductivity gel~* Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.)~* Body mass index greater than 35~* American Society of Anesthesiologists (ASA) score of 3 or greater general anesthesia risk level~* Known sensitivity to possible medications used before, during, or after the ELS procedure, including but not limited to the following: sedative agents, general anaesthetics, topical anaesthetics, and opioid analgesics.~* Enrollment in another research study or previous participation within 30 days of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Enhanced Lithotripsy System (Type: EXPERIMENTAL): Treatment of urinary stones with the Enhanced Lithotripsy System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Colchicine in Hospitalized Colombian Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years old.~* Laboratory-confirmed SARS-CoV-2 infection: infection confirmed with nasopharyngeal swab by positive RT PCR in the last 48 hours.~* Hospital admission for COVID-19 in the previous 48 hours.~* Clinical stage 3 (no supplemental oxygen requirement) or 4 (supplemental oxygen requirement for nasal contact lenses or mask) of the WHO classification (see ANNEX 2).~* The patient must be able and willing to provide informed written consent before performing study procedures.~* Patient confirmed to covid19 as positive by positive PCR test~Exclusion Criteria:~* Pregnancy, nursing mothers, and women of childbearing potential who are unable to use adequate contraception.~* Known hypersensitivity or other clear contraindication to the use of colchicine.~* History of end-stage renal disease (eGFR \<30 ml / min / 1.73 m2).~* Medical history of cirrhosis (Child-Pugh C), liver failure, chronic active hepatitis, or severe liver disease defined by alanine aminotransferase (ALT) or aspartate aminotransferase (AST)\> 5 times the upper limit of normal.~* History of pre-existing neuromuscular disease.~* Previous severe hematologic disease or bleeding disorders.~* Inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea, or malabsorptive syndrome.~* Colchicine treatment for other indications.~* Treatment with immunosuppressive/immunomodulatory agents, including glucocorticoids, antivirals, antimalarials, and IL 6 antagonists for 30 days prior to enrollment.~* Use of other investigational drugs at the time of inclusion, or during the 30 days prior to inclusion.~* Any medical condition or disease that, in the opinion of the investigator, may place the patient at unacceptable risk to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COLHICINE PLUS STANDARD TREATMENT (Type: ACTIVE_COMPARATOR): Patients treated in the exposed group will consist of a decreasing dose of colchicine: a dose of 1.5 mg orally on the first day (initial 1 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
- STANDARD TREATMENT (Type: PLACEBO_COMPARATOR): In this case, the centers where the patients will be included adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases), and to standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: European Active Surveillance Study Comparing Regimens of Administration in Combined Hormonal Contraception

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
There will be no specific medical inclusion/exclusion criteria and no age restrictions~Inclusion Criteria:~* First ever user of a combined hormonal contraceptive starter~* User who restarts a combined hormonal contraceptive after at leat a two month break restarter~* Women willing to participate in an active surveillance study~Exclusion Criteria:~- Women who do not understand the major aspects of the study

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- FC patch low (Type: None): Women taking FC Patch low, a transdermal patch releasing 60 micrograms gestodene/24 hours + 13 micrograms ethinyl estradiol/24 hours
- LNG-COC (Type: None): Women taking levonorgestrel-containing COCs: 1) monophasic preparations containing 20 - 30mcg of ethinylestradiol; 2) multiphasic preparations containing up to 40mcg of ethinylestradiol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Impact of Therapeutic Education Workshops for COPD Patients in the North-West Val d'Oise Area

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Patient aged 18 or over~* Patient living in the NOVO hospital area and the border towns of Yvelines, Oise and Eure~* Patient with a diagnosis of COPD confirmed by EFR, whatever the stage~For PTE group :~- Patient who has already attended at least 3 PTE workshops offered by MPSAT~For Control group :~- Patient on waiting list for PTE workshops offered by MPSAT~Exclusion Criteria :~* Patient refusing to take part in study~* Patient under legal protection~* Patient with cognitive disorders, unstable clinical conditions, language barriers or other conditions that prevent them from understanding the study and answering the questionnaires

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTE group (Type: OTHER): Group composed of patients who have already taken part in at least 3 Patient Therapeutic Education (PTE) workshops at the Maison de Prévention de la Santé et d'Accompagnement Therapeutique (MPSAT)
- Control group (Type: OTHER): Group made up of patients on the waiting list for Patient Therapeutic Education (PTE) workshops at the Maison de Prévention de la Santé et d'Accompagnement Thérapeutique (MPSAT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed locally advanced unresectable or borderline resectable adenocarcinoma of pancreas~* Patients must have measurable disease as defined by RECIST 1.1 RECIST evaluations must have occurred within 4 weeks prior to study entry~* No evidence of hepatic or pulmonary metastatic disease by CT or CT/PET scans~* Male or non-pregnant and non-lactating female age \> or equal to 18 years and \< or equal to 70 years of age~* Patient must have received no prior therapy for the treatment of locally advanced unresectable or borderline resectable pancreatic cancer~* Patients must have adequate blood counts at baseline and blood chemistry levels~* Patient has ECOG Performance Status 0 to 1~Exclusion Criteria:~* Patients with islet cell neoplasms excluded~* Patients with known brain metastases~* Therapeutic Coumadin for a history of pulmonary emboli or deep vein thrombosis (DVT)~* Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy~* Known infection with HIV, hepatitis B or hepatitis C~* Major surgery or vascular device placement within 4 weeks prior to Day 1 of treatment in study~* Prior chemotherapy or radiation for pancreatic cancer~* History of allergy or hypersensitivity to the study drugs~* Patient is enrolled in any other clinical protocol or investigational trial~* Metastatic disease on radiological staging~* Prior malignancy within last 3 years~* Significant cardiac disease~* Any prior gastrointestinal (GI) disease or history of prior pelvic or abdominal radiation in which in opinion of the investigator may place the patient at increased risk~* peripheral sensory neuropathy \> or equal to grade 2 at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- FOLFIRINOX (Type: EXPERIMENTAL): Combination of drugs (Irinotecan, Oxaliplatin, Leucovorin, and 5-Fluorouracil (5-FU)) known as FOLFIRINOX every 2 weeks for 4 treatments. At the end of 4 cycles, patients will be re-evaluated for resectability by CT scan within 28 days of the last dose of chemo. If found amendable to surgery, patient will proceed with resection, and type of resection (R0 or R1) will be recorded.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MRS and Medication Response: A Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Major depressive disorder:~Inclusion Criteria:~1. DSM diagnosis of Major Depressive Disorder~2. Taking paroxetine \[(Paxil) or citalopram (Celexa) or escitalopram (Lexapro)\]for at least 6 weeks~3. Between 21 - 75 years of age.~4. Taking a stable dose of paroxetine \[(Paxil) or citalopram (Celexa) or escitalopram (Lexapro)\] for at least the 2 weeks prior to the imaging session~Healthy controls:~1. Between 21 - 75 years of age.~2. Have a 21-item HAM-D score of less than or equal to 5.~3. No current, or history of any Axis I disorder.~Identify exclusion criteria.~Exclusion criteria are as follows:~1. Contraindications for an MRI exam. These includes biomedical devices such as pacemakers, aneurysm clips, prostheses, and other metallic objects embedded in the body such as bullets, buckshot, shrapnel, and any metal fragments from working around metal.~2. Current pregnancy or lactation.~3. Patients with claustrophobia.~4. History, or current Axis I or Axis II disorders~5. Active unstable medical problems, as confirmed by screening procedures~6. Diagnosed with any autoimmune disease, (e.g., rheumatoid arthritis, Lupus, MLS).~7. Chronic use of steroids or opiates.~8. Positive urine toxicology screen for illicit substances of abuse.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Major depressive disorder (Type: None): There is no intervention/treatment in this study.
- Non-depressed individuals (Type: None): There is no intervention/treatment in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically and radiologically confirmed locally advanced pancreatic ductal adenocarcinoma and have not received prior therapy~* Disease is measurable by CT scan~* Age \>= to 18 years~* Life expectancy of 4 months or longer~* ANC \>/= 1,500mm/cm3~* Hemoglobin \>/= 9g/dl~* Platelet count \>/= 100,000/cm3~* Total bilirubin \</= 2 times control~* SGOT/SGPT \</= 2.5 times upper limit of normal~* Serum creatinine \< 2mg/dl~* No evidence of metastatic disease by laparoscopy~Exclusion Criteria:~* History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk for complications~* No secondary malignancies other than non-melanoma skin cancers or carcinoma in-situ of the cervix within past 5 years~* Patients with pre-existing peripheral neuropathy of grade 2 or greater~* Pregnant or lactating women~* Current, recent (within 4 weeks of study entry) or planned participation in an experimental drug study~* Blood pressure of \>150/100 mmHg~* Unstable angina~* New York Heart Association Grade II or greater congestive heart failure~* History of myocardial infarction or stroke within 6 months~* Clinically significant peripheral vascular disease~* Evidence of bleeding diathesis or coagulopathy~* Presence of central nervous system or brain metastases~* Major surgical procedure, open biopsy,m or significant traumatic injury within 28 days prior to day 0~* Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 0~* Urine protein creatinine ratio \> or = to 1.0 at screening~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 0~* Serious, non-healing wound, ulcer, or bone fracture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regimen Level 1 (Type: EXPERIMENTAL): Radiation/Oxaliplatin/5-FU
- Regimen Level 2 (Type: EXPERIMENTAL): Radiation/Oxaliplatin/Bevacizumab/5-FU

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Dehydrated Cell and Protein Concentrate Versus Corticosteroid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 20 years but less than 75 years old~* Both male and female (non-pregnant)~* Valid knee radiograph within 3 months of beginning treatment;~* Diagnosis of OA of the knee~* OA pain in the knee despite conservative measures~* Average daily VAS \>= 3~* Off any NSAIDs for 1 week prior to injection, may then continue for no more than 5 consecutive days after injection~* Kellgren-Lawrence system of Grade II, III, or IV~Exclusion Criteria:~* Kellgren-Lawrence Grade I~* Tense effusion of the knee~* Significant valgus/varus deformities~* Viscosupplementation within 6 months~* Surgery in the knee within the past 6 months Systemic or intraarticular injection of costicosteroids in any joint within 3 months before screening~* Chronic opioid usage~* History of Leukemia or Lymphoma~* History of any autoimmune disorders and disease~* Immunosuppressive medications~* Active, suspected, or prior infection to the joint~* Vulnerable populations (pregnant women and breast-feeding women, cognitively impaired, prisoners, etc...)~* NSAIDs used within 1 week of the procedure~* History of bleeding disorders or inflammatory joint disease~* Patients who plan on becoming pregnant during study period

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ascent Intervention Treatment (Type: EXPERIMENTAL): Interventional treatment arm will receive Ascent dehydrated cell and protein concentrate injection
- Standard Treatment (Type: ACTIVE_COMPARATOR): Standard treatment arm will receive a standard Corticosteroid injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 65 years;~* breast or lung cancer patients to receive docetaxel therapy as per protocol;~* corticosteroid administration, other than what is prescribed in this protocol, is not permitted during study participation, except topical administration and for adverse events;~* performance status ECOG 0-2;~* peripheral neuropathy ≤ 1;~* adequate kidney and liver functions~* signed study-specific informed consent~Exclusion Criteria:~* Patients who have received an investigational drug within 4 weeks of registration;~* Prior or concurrent malignancies (other than surgically treated carcinoma in situ;~* Serious medical or psychiatric illness which would prevent informed consent;~* Life expectancy \< 3 months;~* Active uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlled.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sensitivity of Frequent SARS-CoV-2 (COVID-19) Rapid Antigen Testing Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: ECOLOGIC_OR_COMMUNITY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older;~* Have a smartphone;~* Understand and read English;~* Will be on one production location for at least three weeks following enrollment to the study;~* Will be willing to be contacted by the Study Coordinator after leaving one production location to facilitate continued access to weekly molecular testing;~Exclusion Criteria:~* Have received any dose of COVID-19 vaccination;~* Have been diagnosed with COVID-19 infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues